Synopsis
Synopsis
0
EU WC
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Akamin
2. Akne Puren
3. Akne-puren
4. Aknemin
5. Aknin Mino
6. Aknin-mino
7. Aknosan
8. Apo Minocycline
9. Apo-minocycline
10. Arestin
11. Blemix
12. Cyclomin
13. Cyclops
14. Dentomycin
15. Dynacin
16. Hydrochloride, Minocycline
17. Icht Oral
18. Icht-oral
19. Klinomycin
20. Lederderm
21. Mestacine
22. Minakne
23. Mino Wolff
24. Mino-wolff
25. Minocin
26. Minocin Mr
27. Minoclir
28. Minocycline
29. Minocycline Monohydrochloride
30. Minocycline, (4r-(4 Alpha,4a Beta,5a Beta,12a Beta))-isomer
31. Minolis
32. Minomycin
33. Minoplus
34. Minotab
35. Minox 50
36. Monohydrochloride, Minocycline
37. Mynocine
1. 13614-98-7
2. Minocycline Hcl
3. Arestin
4. Solodyn
5. Minomycin
6. Minocin
7. Dynacin
8. Periocline
9. Ximino
10. Minocycline (hydrochloride)
11. Vectrin
12. Minomax
13. (4s,4as,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide Hydrochloride
14. Mynocine Hydrochloride
15. Minocycline (as Hydrochloride)
16. Minocycline, Hydrochloride
17. 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide Monohydrochloride
18. 0020414e5u
19. Tri-mino
20. Nsc-141993
21. Dsstox_cid_24545
22. Dsstox_rid_80306
23. Dsstox_gsid_44545
24. (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride
25. [4s-(4alpha,4aalpha,5aalpha,12aalpha)]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide Monohydrochloride
26. Lederderm
27. Mynocine
28. Acnez
29. Minomycin Chloride
30. Chebi:50697
31. (4s-(4alpha,4aalpha,5aalpha,12aalpha))-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide Monohydrochloride
32. [4s-(4?,4a?,5a?,12a?)]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a,tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
33. 2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, Hydrochloride (1:2), (4s,4as,5ar,12as)-
34. Einecs 237-099-7
35. Minocycline Hydrochloride (internal Use)
36. C23h27n3o7.hcl
37. Minocycline, Hcl
38. Unii-0020414e5u
39. Ncgc00096006-01
40. Prestwick_626
41. Arestin (tn)
42. Dynacin (tn)
43. Minocin (tn)
44. Solodyn (tn)
45. Minocycline Hydrochloride [usp:jan]
46. 7-dimethylamino-6-demethyl-6-deoxytetracycline, Hcl
47. Mfcd00083669
48. Minocyclinhydrochlorid
49. Amzeeq
50. Minolira
51. Zilxi
52. Minomycin Hydrochloride
53. Schembl2537
54. Cas-13614-98-7
55. 2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, Monohydrochloride, (4s-(4alpha,4aalpha,5aalpha,12aalpha))-
56. Mls002548863
57. Spectrum1500414
58. Fxfm-244
59. Chembl1200881
60. Chembl4576719
61. Dtxsid8044545
62. Hms1568p12
63. Pharmakon1600-01500414
64. Bcp06597
65. Tox21_111250
66. Tox21_113183
67. Tox21_301590
68. Ccg-40107
69. Nsc757120
70. S4226
71. Minocycline Hydrochloride [mi]
72. Minocycline Hydrochloride, Crystalline
73. Akos015951312
74. Minocycline Hydrochloride (jp17/usp)
75. Tox21_111250_1
76. Cs-1256
77. Minocycline Hydrochloride [jan]
78. Nc00460
79. Nsc-757120
80. Minocycline Hydrochloride [mart.]
81. Minocycline Hydrochloride [vandf]
82. Ncgc00178854-03
83. Ncgc00255988-01
84. Ac-22362
85. As-75306
86. Hy-17412
87. Minocycline Hydrochloride [usp-rs]
88. Minocycline Hydrochloride [who-dd]
89. Smr001906766
90. M2288
91. D00850
92. Minocycline Hydrochloride [orange Book]
93. Minocycline Hydrochloride [usp Monograph]
94. 614m987
95. Sr-01000075625
96. Q-201407
97. Sr-01000075625-1
98. Q27104777
99. Minocycline Hydrochloride, Antibiotic For Culture Media Use Only
100. Minocycline Hydrochloride, European Pharmacopoeia (ep) Reference Standard
101. Minocycline Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
102. Minocycline Hydrochloride, United States Pharmacopeia (usp) Reference Standard
103. (4s,12as,4as,5ar)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide Hydrochloride
104. (4s,4as,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamidehydrochloride
105. 2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, Monohydrochloride, (4s-(4.alpha.,4a.alpha.,5a.alpha.,12a.alpha.))-
Molecular Weight | 493.9 g/mol |
---|---|
Molecular Formula | C23H28ClN3O7 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 3 |
Exact Mass | 493.1615779 g/mol |
Monoisotopic Mass | 493.1615779 g/mol |
Topological Polar Surface Area | 165 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 971 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 10 | |
---|---|
Drug Name | Arestin |
PubMed Health | Minocycline |
Drug Classes | Amebicide, Intestinal, Antiacne, Antiacne Antibacterial, Antibiotic, Antiprotozoal, Tetracycline |
Drug Label | ARESTIN (minocycline hydrochloride) Microspheres is a subgingival sustained-release product containing the antibiotic minocycline hydrochloride incorporated into a bioresorbable polymer, Poly (glycolide-co-dl-lactide) or PGLA, for professional subg... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Powder, extended release |
Route | Dental |
Strength | eq 1mg base |
Market Status | Prescription |
Company | Orapharma |
2 of 10 | |
---|---|
Drug Name | Dynacin |
Drug Label | Minocycline hydrochloride, is a semisynthetic derivative of tetracycline, 4,7-Bis(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1, 11-dioxo-2naphthacenecarboxamide monohydrochloride. Its structural formula is:C23H27N3O7... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 100mg base; eq 75mg base |
Market Status | Prescription |
Company | Cnty Line Pharms |
3 of 10 | |
---|---|
Drug Name | Minocin |
PubMed Health | Minocycline, Regular Release (By mouth) |
Drug Classes | Amebicide, Intestinal, Antiacne, Antibiotic, Antiprotozoal |
Drug Label | MINOCIN minocycline hydrochloride, is a semisynthetic derivative of tetracycline, 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride.Its structural formula is:C23H27N... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Capsule; Injectable |
Route | Injection; Oral |
Strength | eq 100mg base; eq 50mg base; eq 100mg base/vial |
Market Status | Prescription |
Company | Rempex Pharms; Precision Dermat |
4 of 10 | |
---|---|
Drug Name | Minocycline hydrochloride |
Drug Label | To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are pr... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Tablet, extended release; Tablet; Capsule |
Route | oral; Oral |
Strength | 65mg; 115mg; eq 100mg base; eq 50mg base; eq 105mg base; eq 65mg base; eq 115mg base; eq 75mg base; eq 90mg base; eq 80mg base; 55mg; eq 45mg base; eq 55mg base; eq 135mg base |
Market Status | Tentative Approval; Prescription |
Company | Mylan Pharms; Ranbaxy; Teva; Mylan Labs; Sun Pharm Inds; Aurobindo Pharma; Lupin; Barr Labs; Sandoz; Par Pharm; Watson Labs; Ranbaxy Labs; Dr Reddys Labs; Impax Labs |
5 of 10 | |
---|---|
Drug Name | Solodyn |
PubMed Health | Minocycline |
Drug Classes | Amebicide, Intestinal, Antiacne, Antiacne Antibacterial, Antibiotic, Antiprotozoal, Tetracycline |
Drug Label | Minocycline hydrochloride, a semi synthetic derivative of tetracycline, is [4S-(4,4a,5a,12a)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono hydrochloride. The structura... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | eq 105mg base; eq 65mg base; eq 115mg base; eq 80mg base; eq 55mg base |
Market Status | Prescription |
Company | Medicis |
6 of 10 | |
---|---|
Drug Name | Arestin |
PubMed Health | Minocycline |
Drug Classes | Amebicide, Intestinal, Antiacne, Antiacne Antibacterial, Antibiotic, Antiprotozoal, Tetracycline |
Drug Label | ARESTIN (minocycline hydrochloride) Microspheres is a subgingival sustained-release product containing the antibiotic minocycline hydrochloride incorporated into a bioresorbable polymer, Poly (glycolide-co-dl-lactide) or PGLA, for professional subg... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Powder, extended release |
Route | Dental |
Strength | eq 1mg base |
Market Status | Prescription |
Company | Orapharma |
7 of 10 | |
---|---|
Drug Name | Dynacin |
Drug Label | Minocycline hydrochloride, is a semisynthetic derivative of tetracycline, 4,7-Bis(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1, 11-dioxo-2naphthacenecarboxamide monohydrochloride. Its structural formula is:C23H27N3O7... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 100mg base; eq 75mg base |
Market Status | Prescription |
Company | Cnty Line Pharms |
8 of 10 | |
---|---|
Drug Name | Minocin |
PubMed Health | Minocycline, Regular Release (By mouth) |
Drug Classes | Amebicide, Intestinal, Antiacne, Antibiotic, Antiprotozoal |
Drug Label | MINOCIN minocycline hydrochloride, is a semisynthetic derivative of tetracycline, 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride.Its structural formula is:C23H27N... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Capsule; Injectable |
Route | Injection; Oral |
Strength | eq 100mg base; eq 50mg base; eq 100mg base/vial |
Market Status | Prescription |
Company | Rempex Pharms; Precision Dermat |
9 of 10 | |
---|---|
Drug Name | Minocycline hydrochloride |
Drug Label | To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are pr... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Tablet, extended release; Tablet; Capsule |
Route | oral; Oral |
Strength | 65mg; 115mg; eq 100mg base; eq 50mg base; eq 105mg base; eq 65mg base; eq 115mg base; eq 75mg base; eq 90mg base; eq 80mg base; 55mg; eq 45mg base; eq 55mg base; eq 135mg base |
Market Status | Tentative Approval; Prescription |
Company | Mylan Pharms; Ranbaxy; Teva; Mylan Labs; Sun Pharm Inds; Aurobindo Pharma; Lupin; Barr Labs; Sandoz; Par Pharm; Watson Labs; Ranbaxy Labs; Dr Reddys Labs; Impax Labs |
10 of 10 | |
---|---|
Drug Name | Solodyn |
PubMed Health | Minocycline |
Drug Classes | Amebicide, Intestinal, Antiacne, Antiacne Antibacterial, Antibiotic, Antiprotozoal, Tetracycline |
Drug Label | Minocycline hydrochloride, a semi synthetic derivative of tetracycline, is [4S-(4,4a,5a,12a)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono hydrochloride. The structura... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | eq 105mg base; eq 65mg base; eq 115mg base; eq 80mg base; eq 55mg base |
Market Status | Prescription |
Company | Medicis |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-07-02
Pay. Date : 2013-06-20
DMF Number : 13758
Submission : 1998-09-01
Status : Active
Type : II
Certificate Number : R1-CEP 1999-002 - Rev 06
Issue Date : 2022-12-02
Type : Chemical
Substance Number : 1030
Status : Valid
Registration Number : 304MF10123
Registrant's Address : Rua da Estacao, 1 e 1A, 2600-726 Castanheira do Ribatejo, Portugal
Initial Date of Registration : 2022-08-17
Latest Date of Registration :
NDC Package Code : 17158-0900
Start Marketing Date : 2017-03-07
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2024-01-31
Registration Number : 20240131-211-J-1572
Manufacturer Name : CIPAN - Companhia Industrial Produtora de Antibióticos, SA
Manufacturer Address : Rua da Estação, 1/1A, 2600-726 Castanheira do Ribatejo, Portugal
Capital Farma, a leading European pharmaceutical company focusing on the development & distribution of niche APIs & Pharma Services.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26050
Submission : 2012-07-20
Status : Active
Type : II
NDC Package Code : 58623-0133
Start Marketing Date : 2019-09-04
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15014
Submission : 2000-10-02
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-01-15
Pay. Date : 2012-12-14
DMF Number : 13738
Submission : 1998-09-01
Status : Active
Type : II
Certificate Number : R0-CEP 2022-299 - Rev 00
Issue Date : 2022-10-11
Type : Chemical
Substance Number : 1030
Status : Valid
Registration Number : 219MF10124
Registrant's Address : Sete Casas 2674-506 Loures PORTUGAL
Initial Date of Registration : 2007-04-18
Latest Date of Registration :
NDC Package Code : 50909-9201
Start Marketing Date : 2015-01-12
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13748
Submission : 1998-09-01
Status : Inactive
Type : II
Certificate Number : R0-CEP 1999-072 - Rev 02
Issue Date : 2004-08-20
Type : Chemical
Substance Number : 1030
Status : Withdrawn by Holder
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2408
Submission : 1975-02-26
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13404
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7849
Submission : 1989-01-04
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-07-02
Pay. Date : 2013-06-20
DMF Number : 13758
Submission : 1998-09-01
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-01-30
Pay. Date : 2013-01-16
DMF Number : 14802
Submission : 2000-03-22
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-01-15
Pay. Date : 2012-12-14
DMF Number : 13738
Submission : 1998-09-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15014
Submission : 2000-10-02
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13755
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7849
Submission : 1989-01-04
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13748
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13404
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2408
Submission : 1975-02-26
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26050
Submission : 2012-07-20
Status : Active
Type : II
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Cyclimycin
Dosage Form : CAP
Dosage Strength : 50mg
Packaging : 60X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Cyclimycin
Dosage Form : CAP
Dosage Strength : 100mg
Packaging : 100X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info :
Registration Country : Australia
Brand Name : Minomycin-50
Dosage Form : tablet
Dosage Strength : 50 mg
Packaging : 60
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Minomycin-50
Dosage Form : tablet
Dosage Strength : 50 mg
Packaging : 60
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info : RX
Registration Country : USA
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 50MG BASE
Packaging :
Approval Date : 2003-04-16
Application Number : 65131
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 75MG BASE
Packaging :
Approval Date : 2003-04-16
Application Number : 65131
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 100MG BASE
Packaging :
Approval Date : 2003-04-16
Application Number : 65131
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 75MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
RLD : No
TE Code : AB
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 50MG BASE
Approval Date : 2003-04-16
Application Number : 65131
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 75MG BASE
Approval Date : 2003-04-16
Application Number : 65131
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 100MG BASE
Approval Date : 2003-04-16
Application Number : 65131
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 75MG BASE
Approval Date : 1999-06-10
Application Number : 63065
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : EQ 80MG BASE
Approval Date : 2016-09-28
Application Number : 204453
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : EQ 135MG BASE
Approval Date : 2012-11-19
Application Number : 202261
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 75MG BASE
Approval Date : 2020-05-01
Application Number : 213662
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : EQ 65MG BASE
Approval Date : 2012-05-18
Application Number : 65485
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : Yes
TE Code :
Brand Name : SOLODYN
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 2006-05-08
Application Number : 50808
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : ZILXI
Dosage Form : AEROSOL, FOAM;TOPICAL
Dosage Strength : EQ 1.5% BASE
Approval Date : 2020-05-28
Application Number : 213690
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
100
PharmaCompass offers a list of Minocycline Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Minocycline Hydrochloride manufacturer or Minocycline Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Minocycline Hydrochloride manufacturer or Minocycline Hydrochloride supplier.
PharmaCompass also assists you with knowing the Minocycline Hydrochloride API Price utilized in the formulation of products. Minocycline Hydrochloride API Price is not always fixed or binding as the Minocycline Hydrochloride Price is obtained through a variety of data sources. The Minocycline Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A FXFM-244 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of FXFM-244, including repackagers and relabelers. The FDA regulates FXFM-244 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. FXFM-244 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of FXFM-244 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A FXFM-244 supplier is an individual or a company that provides FXFM-244 active pharmaceutical ingredient (API) or FXFM-244 finished formulations upon request. The FXFM-244 suppliers may include FXFM-244 API manufacturers, exporters, distributors and traders.
click here to find a list of FXFM-244 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A FXFM-244 DMF (Drug Master File) is a document detailing the whole manufacturing process of FXFM-244 active pharmaceutical ingredient (API) in detail. Different forms of FXFM-244 DMFs exist exist since differing nations have different regulations, such as FXFM-244 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A FXFM-244 DMF submitted to regulatory agencies in the US is known as a USDMF. FXFM-244 USDMF includes data on FXFM-244's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The FXFM-244 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of FXFM-244 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The FXFM-244 Drug Master File in Japan (FXFM-244 JDMF) empowers FXFM-244 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the FXFM-244 JDMF during the approval evaluation for pharmaceutical products. At the time of FXFM-244 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of FXFM-244 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a FXFM-244 Drug Master File in Korea (FXFM-244 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of FXFM-244. The MFDS reviews the FXFM-244 KDMF as part of the drug registration process and uses the information provided in the FXFM-244 KDMF to evaluate the safety and efficacy of the drug.
After submitting a FXFM-244 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their FXFM-244 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of FXFM-244 suppliers with KDMF on PharmaCompass.
A FXFM-244 CEP of the European Pharmacopoeia monograph is often referred to as a FXFM-244 Certificate of Suitability (COS). The purpose of a FXFM-244 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of FXFM-244 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of FXFM-244 to their clients by showing that a FXFM-244 CEP has been issued for it. The manufacturer submits a FXFM-244 CEP (COS) as part of the market authorization procedure, and it takes on the role of a FXFM-244 CEP holder for the record. Additionally, the data presented in the FXFM-244 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the FXFM-244 DMF.
A FXFM-244 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. FXFM-244 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of FXFM-244 suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing FXFM-244 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for FXFM-244 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture FXFM-244 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain FXFM-244 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a FXFM-244 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of FXFM-244 suppliers with NDC on PharmaCompass.
FXFM-244 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of FXFM-244 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right FXFM-244 GMP manufacturer or FXFM-244 GMP API supplier for your needs.
A FXFM-244 CoA (Certificate of Analysis) is a formal document that attests to FXFM-244's compliance with FXFM-244 specifications and serves as a tool for batch-level quality control.
FXFM-244 CoA mostly includes findings from lab analyses of a specific batch. For each FXFM-244 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
FXFM-244 may be tested according to a variety of international standards, such as European Pharmacopoeia (FXFM-244 EP), FXFM-244 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (FXFM-244 USP).